Literature DB >> 176393

Antibody-dependent lymphocyte cytotoxicity against cells expressing Epstein-Barr virus antigens.

G R Pearson, T W Orr.   

Abstract

Antibody-dependent lymphocyte cytotoxicity (ADLC) was demonstrated against Epstein-Barr virus (EBV)-infected RAJI cells with peripheral with peripheral blood lymphocytes from EBV-infected donors. No cytotoxic activity was detected against unifected RAJl cells. The results indicated that this antibody-mediated cytotoxic reaction was directed against the same EBV-induced membrane antigens (MA) previously defined by the membrane immunofluorescence (MF) assay. Antibody to EBV-associated early antigens did not participate in this in vitro reaction. Antibody titers to EBV-induced MA were significantly higher by the ADLC assay in comparison with the MF test. A preliminary study showed no relationship between high antibody titers and the presence of EBV-associated malignancies. The possible in vivo significance of this immune reaction was discussed.

Entities:  

Mesh：

Substances：

Year:  1976        PMID： 176393     DOI： 10.1093/jnci/56.3.485

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN： 0027-8874            Impact factor:   13.506


  22 in total

1.  Heterogeneity of human lymphocyte Fc receptors. II. Relationship to antibody-dependent, cell-mediated cytotoxicity.

Authors:  B J Gormus; M Woodson; M E Kaplan
Journal:  Clin Exp Immunol       Date:  1978-11       Impact factor: 4.330

2.  Subcellular distribution and life cycle of Epstein-Barr virus in keratinocytes of oral hairy leukoplakia.

Authors:  J P Rabanus; D Greenspan; V Petersen; U Leser; H Wolf; J S Greenspan
Journal:  Am J Pathol       Date:  1991-07       Impact factor: 4.307

3.  Epstein-Barr virus (EBV) glycoprotein gp350 expressed on transfected cells resistant to natural killer cell activity serves as a target antigen for EBV-specific antibody-dependent cellular cytotoxicity.

Authors:  M Khyatti; P C Patel; I Stefanescu; J Menezes
Journal:  J Virol       Date:  1991-02       Impact factor: 5.103

4.  The mother lode of liver transplantation, with particular reference to our new journal.

Authors:  T E Starzl
Journal:  Liver Transpl Surg       Date:  1998-01

5.  Autologous lymphokine-activated killer cell therapy of lymphoproliferative disorders arising in organ transplant recipients.

Authors:  M A Nalesnik; A S Rao; A Zeevi; J J Fung; S Pham; H Furukawa; A Gritsch; G Klein; T E Starzl
Journal:  Transplant Proc       Date:  1997-05       Impact factor: 1.066

6.  Papain solubilization of the Epstein-Barr virus-induced membrane antigen.

Authors:  G R Pearson; L F Qualtiere
Journal:  J Virol       Date:  1978-10       Impact factor: 5.103

7.  Antibody-dependent cell-mediated cytotoxicity against Escherichia coli O antigens.

Authors:  M Hagberg; S Ahlstedt; L Hanson
Journal:  Eur J Clin Microbiol       Date:  1982-02       Impact factor: 3.267

8.  Monoclonal antibodies against the major glycoprotein (gp350/220) of Epstein-Barr virus neutralize infectivity.

Authors:  D A Thorley-Lawson; K Geilinger
Journal:  Proc Natl Acad Sci U S A       Date:  1980-09       Impact factor: 11.205

9.  Epstein-Barr serology in immunodeficiencies: an attempt to correlate with immune abnormalities in Wiskott-Aldrich and Chediak-Higashi syndromes and ataxia telangiectasia.

Authors:  E Vilmer; G M Lenoir; J L Virelizier; C Griscelli
Journal:  Clin Exp Immunol       Date:  1984-02       Impact factor: 4.330

10.  p105, an Epstein-Barr virus-induced, phosphonoacetic acid-insensitive glycoprotein target of the anti-Epstein-Barr virus immune response.

Authors:  D Casareale; W Jones; T Sairenji; R E Humphreys
Journal:  Infect Immun       Date:  1983-01       Impact factor: 3.441
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.